Covalon's compassionate care technology is
quickly becoming a standard of care in more than 17% of pediatric
hospitals in the US.
MISSISSAUGA, ON, Sept. 8,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical
technologies company, today announced it has now grown its
pediatric hospital customer base to over 40 pediatric hospitals,
which represents more than 17% of United
States pediatric hospitals. All these hospitals have
adopted at least one of Covalon's patented infection prevention
products to help prevent bloodstream and/or surgical site
infections and improve patient outcomes. Becoming standard of care
in a significant number of pediatric hospitals provides a strong
base for Covalon to grow its presence in additional children's
hospitals.
Covalon's suite of compassionate care solutions has been
designed to treat the most vulnerable patients and has been
successful in improving the standard of care in key pediatric
hospitals. Pediatric patients – from birth to 18 years of age –
have a different physiology than adult patients and require
tailored medical care that best suits their age and unique medical
needs. There are more than 250 pediatric hospitals in the United States, and they provide over 95%
of transplantations, cancer programs, and tertiary care to
children.
"It is not a mystery why 8 of the top 10 pediatric hospitals for
cancer treatment in the United
States are using Covalon products," said Brian Pedlar, CEO of Covalon. "Our products are
specifically designed to help these patients heal better and safer,
as recognized by health care providers that have dedicated
themselves to the healing of some of our most vulnerable patients –
our children."
To date, four of the top five pediatric hospitals in
the United States, as ranked by
U.S. News & World Report, have adopted at least one of
Covalon's products as part of their infection prevention protocols
to reduce infections. The unique dual-antimicrobial and soft
silicone adhesive technology of IV Clear and SurgiClear has been
shown to improve peri-wound healing and patient skin integrity,
helping clinicians achieve better patient outcomes.
"Our products are made for patients but designed for care
providers. We expect to continue seeing hospitals adopting
Covalon's patented infection prevention products to help reduce
bloodstream and surgical site infections, while improving patient
outcomes," continues Brian.
Leading pediatric hospitals have also reported that Covalon's
products allow for better monitoring and observation of the
surgical site or insertion site by caregivers. The transparent
nature of IV Clear and SurgiClear removes the need for frequent
dressing changes and allows regular visual site assessment without
disturbing the surgical or insertion site because the antimicrobial
silicone adhesive dressings can remain in place for up to seven
days. At discharge, health care providers found it easier to
educate patients' families about how to monitor their child for
signs of complications.
Covalon's patented products include:
- VALGuard® - an FDA-approved, transparent,
environmental barrier designed to protect catheter hubs and line
connections from external contaminants and gross contamination,
including body fluids and other secretions. It incorporates a
quick-release pull strip for fast access to infusion hubs and for
easy removal.
- SurgiClear® - a transparent, breathable, fluid
impermeable barrier that isolates the wound site from external
contamination, while providing dual antimicrobial protection
throughout the entire surface of the dressing. It uses a low but
effective concentration of chlorhexidine and silver, embedded into
an atraumatic silicone adhesive that covers the entire transparent
surface area to allow for easy and consistent monitoring of wound
sites.
- IV Clear® - a vascular access dressing that offers
complete transparency at and around the insertion site for easy
daily assessment. It uses a soft silicone adhesive to preserve the
skin's barrier function and minimize skin injuries and incorporates
safe amounts of antimicrobials, without sacrificing efficacy, to
protect against chemical irritation.
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTQX Market under
the symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
three and nine months ended June 30,
2022, which is available on the Company's profile at
www.sedar.com, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Investors should not
place undue reliance on any forward-looking statements. The
forward-looking statements contained in this news release are made
as of the date of this news release, and the Company assumes no
obligation to update or alter any forward-looking statements,
whether as a result of new information, further events or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-expansion-of-its-united-states-pediatric-hospital-customer-base-301620344.html
SOURCE Covalon Technologies Ltd.